Nature Communications (Mar 2017)
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation
- Inga-Marie Schaefer,
- Yuexiang Wang,
- Cher-wei Liang,
- Nacef Bahri,
- Anna Quattrone,
- Leona Doyle,
- Adrian Mariño-Enríquez,
- Alexandra Lauria,
- Meijun Zhu,
- Maria Debiec-Rychter,
- Susanne Grunewald,
- Jaclyn F. Hechtman,
- Armelle Dufresne,
- Cristina R. Antonescu,
- Carol Beadling,
- Ewa T. Sicinska,
- Matt van de Rijn,
- George D. Demetri,
- Marc Ladanyi,
- Christopher L. Corless,
- Michael C. Heinrich,
- Chandrajit P. Raut,
- Sebastian Bauer,
- Jonathan A. Fletcher
Affiliations
- Inga-Marie Schaefer
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Yuexiang Wang
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Cher-wei Liang
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Nacef Bahri
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Anna Quattrone
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Leona Doyle
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Adrian Mariño-Enríquez
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Alexandra Lauria
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Meijun Zhu
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Maria Debiec-Rychter
- Department of Human Genetics, KU Leuven and University Hospitals Leuven
- Susanne Grunewald
- Sarcoma Center, Western German Cancer Center, University of Duisburg-Essen Medical School
- Jaclyn F. Hechtman
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
- Armelle Dufresne
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- Cristina R. Antonescu
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
- Carol Beadling
- Department of Pathology, Knight Cancer Institute, Oregon Health and Science University
- Ewa T. Sicinska
- Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School
- Matt van de Rijn
- Department of Pathology, Stanford University Medical Center
- George D. Demetri
- Harvard Medical School and Department of Medical Oncology, Ludwig Center at Harvard, Dana-Farber Cancer Institute
- Marc Ladanyi
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
- Christopher L. Corless
- Department of Pathology, Knight Cancer Institute, Oregon Health and Science University
- Michael C. Heinrich
- Portland VA Health Care System, Knight Cancer Institute, Oregon Health and Science University
- Chandrajit P. Raut
- Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School
- Sebastian Bauer
- Sarcoma Center, Western German Cancer Center, University of Duisburg-Essen Medical School
- Jonathan A. Fletcher
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/ncomms14674
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 6
Abstract
In gastrointestinal stromal tumours early mutations in known genes are frequently followed by chromosome 14q deletion. Here the authors find mutations resulting in loss of MAX protein expression conserved between primary tumours and metastases in the same patients, suggesting thatMAXmutation is an early event.
